

DAFTAR PUSTAKA

- Alasmari, W.A. *et al.* (2022) 'Exosomes derived from BM-mscs mitigate the development of chronic kidney damage post-menopause via interfering with fibrosis and apoptosis', *Biomolecules*, 12(5), p. 663. doi:10.3390/biom12050663.
- Ammirati, A.L. (2020) 'Chronic kidney disease', *Revista da Associação Médica Brasileira*, 66(suppl 1). doi:10.1590/1806-9282.66.s1.3.
- Badura, K. *et al.* (2024) 'Anemia of Chronic Kidney Disease—A Narrative Review of its Pathophysiology, Diagnosis, and Management,' *Biomedicines*, 12(6), p. 1191. <https://doi.org/10.3390/biomedicines12061191>.
- Black, L.M., Lever, J.M. and Agarwal, A. (2019) 'Renal inflammation and fibrosis: a double-edged sword,' *Journal of Histochemistry & Cytochemistry*, 67(9), pp. 663–681. <https://doi.org/10.1369/0022155419852932>.
- Bui, T.M., Wiesolek, H.L. and Sumagin, R. (2020) 'ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis', *Journal of Leukocyte Biology*, 108(3), pp. 787–799. doi:10.1002/jlb.2mr0220-549r.
- Cahyawati, P.N. and Satriyasa, B.K. (2021) 'Subtotal nephrectomy as a model of chronic kidney disease: A systematic review', *Indian Journal of Public Health Research & Development*, 12(3), pp. 150–157. doi:10.37506/ijphrd.v12i3.16058.
- Cao, J.-Y. *et al.* (2021) 'Exosomal mir-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury', *Theranostics*, 11(11), pp. 5248–5266. doi:10.7150/thno.54550.
- Cao, Q. *et al.* (2022) 'Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in chronic kidney disease', *Frontiers in Medicine*, 9. doi:10.3389/fmed.2022.816656.
- Cargnoni, A. *et al.* (2021) 'Extracellular vesicles from perinatal cells for anti-inflammatory therapy', *Frontiers in Bioengineering and Biotechnology*, 9. doi:10.3389/fbioe.2021.637737.
- Ceccotti, E. *et al.* (2025) 'Mesenchymal stem cells derived extracellular vesicles for chronic kidney disease: Pleiotropic mechanisms of actions of a versatile therapy', *Frontiers in Bioengineering and Biotechnology*, 13. doi:10.3389/fbioe.2025.1612193.

- Chang, C. *et al.* (2021) 'Effects of mesenchymal Stem Cell-Derived paracrine signals and their delivery strategies,' *Advanced Healthcare Materials*, 10(7). <https://doi.org/10.1002/adhm.202001689>.
- Chen, T.K., Knicely, D.H. and Grams, M.E. (2019) 'Chronic kidney disease diagnosis and management', *JAMA*, 322(13), p. 1294. doi:10.1001/jama.2019.14745.
- Chen, F. *et al.* (2023) 'Mesenchymal stem cell therapy in kidney diseases: Potential and challenges', *Cell Transplantation*, 32, p. 096368972311642. doi:10.1177/09636897231164251.
- Chuang, Y., Hsu, Y. and Li, C. (2017) 'Luteolin inhibits indoxyl sulfate-induced inflammation through suppression of NF-kB activation in human endothelial cells,' *The FASEB Journal*, 31(S1). https://doi.org/10.1096/fasebj.31.1_supplement.972.1.
- Dong, B. *et al.* (2021) 'Exosomes from human umbilical cord mesenchymal stem cells attenuate the inflammation of severe steroid-resistant asthma by reshaping macrophage polarization', *Stem Cell Research & Therapy*, 12(1). doi:10.1186/s13287-021-02244-6.
- Fattah, H., Layton, A. and Vallon, V. (2019) 'How do kidneys adapt to a deficit or loss in nephron number?,' *Physiology*, 34(3), pp. 189–197. <https://doi.org/10.1152/physiol.00052.2018>.
- Feng, Y.-M. *et al.* (2017) 'Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population,' *Nephrology Dialysis Transplantation*, 33(3), pp. 426–435. <https://doi.org/10.1093/ndt/gfx256>.
- Garton, K.J. *et al.* (2003) 'Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis Factor- α -converting enzyme (ADAM 17),' *Journal of Biological Chemistry*, 278(39), pp. 37459–37464. <https://doi.org/10.1074/jbc.m305877200>.
- Gasparin, A.A. *et al.* (2020) 'Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis', *BMC Rheumatology*, 4(1). doi:10.1186/s41927-020-00162-3.
- Gelis, T.N. *et al.* (2020) 'HISTOPATOLOGI GINJAL TIKUS PUTIH (*Rattus norvegicus*) SETELAH IMPLAN WIRE MATERIAL LOGAM', *Jurnal Ilmiah Mahasiswa Veteriner (JIMVET) Fakultas Kedokteran Hewan Universitas Syiah Kuala*, 4(4), pp. 101–106.

Habib, S.A. *et al.* (2022) 'Biochemical and histopathological evaluations of chronic renal failure rats treated with pluripotent human stem cells', *Brazilian Journal of Pharmaceutical Sciences*, 58. doi:10.1590/s2175-97902022e20089.

Harahap, D.H. and Irdam, G.A. (2022) 'Human umbilical cords mesenchymal stem cells for kidney diseases', *Bali Medical Journal*, 11(1), pp. 155–159. doi:10.15562/bmj.v11i1.3085.

Haydinger, C.D. *et al.* (2023) 'Intercellular adhesion molecule 1: More than A leukocyte adhesion molecule', *Biology*, 12(5), p. 743. doi:10.3390/biology12050743.

Harrell, C.R. *et al.* (2019) 'Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases', *Cells*, 8(12), p. 1605. doi:10.3390/cells8121605.

Hidayangsih, P.S. *et al.* (2023) 'Chronic kidney disease in Indonesia: Evidence from a National Health Survey', *Osong Public Health and Research Perspectives*, 14(1), pp. 23–30. doi:10.24171/j.phrp.2022.0290.

Himanshu *et al.* (2025) 'Meta-analysis study of the therapeutic impact of mesenchymal stem cells derived exosomes for chronic kidney diseases', *Biochemistry and Biophysics Reports*, 43, p. 102072. doi:10.1016/j.bbrep.2025.102072.

Hodgkins, K.S. and Schnaper, H.W. (2011) 'Tubulointerstitial injury and the progression of chronic kidney disease,' *Pediatric Nephrology*, 27(6), pp. 901–909. <https://doi.org/10.1007/s00467-011-1992-9>.

Homma, K. *et al.* (2023) 'A combination of 5/6-nephrectomy and unilateral ureteral obstruction model accelerates progression of remote organ fibrosis in chronic kidney disease', *FASEB BioAdvances*, 5(10), pp. 377–394. doi:10.1096/fba.2023-00045.

- Huang, J. *et al.* (2022) 'Mesenchymal stem cells-derived exosomes ameliorate ischemia/reperfusion induced acute kidney injury in a porcine model', *Frontiers in Cell and Developmental Biology*, 10. doi:10.3389/fcell.2022.899869.
- Hustrini, N.M. (2024) 'The etiology of Advanced Chronic Kidney Disease in Southeast Asia: A meta-analysis', *Journal of Epidemiology and Global Health* [Preprint]. doi:10.1007/s44197-024-00209-5.
- Ji, C. *et al.* (2020) 'Exosomes derived from hucMSC attenuate renal fibrosis through CK1 Δ / β -TRCP-mediated YAP degradation', *Cell Death & Disease*, 11(5). doi:10.1038/s41419-020-2510-4.
- Kadatane, S.P. *et al.* (2023) 'The role of inflammation in CKD,' *Cells*, 12(12), p. 1581. <https://doi.org/10.3390/cells12121581>.
- Kalluri, R. and LeBleu, V.S. (2020) 'The biology, function, and biomedical applications of exosomes', *Science*, 367(6478). doi:10.1126/science.aau6977.
- Kanbay, M. *et al.* (2024) 'Glomerular hyperfiltration as a therapeutic target for CKD,' *Nephrology Dialysis Transplantation*, 39(8), pp. 1228–1238. <https://doi.org/10.1093/ndt/gfae027>.
- KDIGO (2013) 'Chapter 1: Definition and classification of CKD', *Kidney International Supplements*, 3(1), pp. 19–62. doi:10.1038/kisup.2012.64.
- Kong, D.-H. *et al.* (2018) 'Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer', *International Journal of Molecular Sciences*, 19(4), p. 1057. doi:10.3390/ijms19041057.
- Lechleitner, S. *et al.* (1998) 'Interferon enhances tumor necrosis factor–induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1–dependent pathway,' *The Journal of Experimental Medicine*, 187(12), pp. 2023–2030. <https://doi.org/10.1084/jem.187.12.2023>.
- Lee, P.-T. *et al.* (2021) 'Expression of Vascular Cell Adhesion Molecule-1 in Peripheral Artery Disease is Enriched in Patients with Advanced Kidney Disease', *Acta Cardiol Sin*, 37(6), pp. 591–599. doi:10.6515/ACS.202111_37(6).20210701B.
- Levey, A.S. *et al.* (2010) 'The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report,' *Kidney International*, 80(1), pp. 17–28. <https://doi.org/10.1038/ki.2010.483>.

- Li, S., Wang, F. and Sun, D. (2021) 'The renal microcirculation in chronic kidney disease: novel diagnostic methods and therapeutic perspectives,' *Cell & Bioscience*, 11(1). <https://doi.org/10.1186/s13578-021-00606-4>.
- Liu, B. *et al.* (2018) 'Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-KB signaling pathway in vivo and in vitro', *Stem Cell Research & Therapy*, 9(1). doi:10.1186/s13287-017-0760-6.
- Liu, B. *et al.* (2021) 'Exosomes released by human umbilical cord mesenchymal stem cells protect against renal interstitial fibrosis through ROS-mediated P38MAPK/erk signaling pathway', *American journal of translational research*, 12(9).
- Liu, J. *et al.* (2019) 'Xenogeneic transplantation of human placenta-derived mesenchymal stem cells alleviates renal injury and reduces inflammation in a mouse model of lupus nephritis', *BioMed Research International*, 2019, pp. 1–11. doi:10.1155/2019/9370919.
- Liu, Y. (2011) 'Cellular and molecular mechanisms of renal fibrosis,' *Nature Reviews Nephrology*, 7(12), pp. 684–696. <https://doi.org/10.1038/nrneph.2011.149>.
- Maringhini, S. and Zoccali, C. (2024) 'Chronic kidney disease progression—a challenge', *Biomedicines*, 12(10), p. 2203. doi:10.3390/biomedicines12102203.
- McArdle, Z. *et al.* (2020) 'Physiology and pathophysiology of compensatory adaptations of a solitary functioning kidney,' *Frontiers in Physiology*, 11. <https://doi.org/10.3389/fphys.2020.00725>.
- Mehta, R. L. (2015). Challenges and pitfalls when implementing renal replacement therapy in the ICU. *Critical Care*, 19(S3). <https://doi.org/10.1186/cc14727>
- Melchinger, I. *et al.* (2024a) 'VCAM-1 mediates proximal tubule-immune cell cross talk in failed tubule recovery during aki-to-CKD transition', *American Journal of Physiology-Renal Physiology*, 327(4). doi:10.1152/ajprenal.00076.2024.
- Murton, M. *et al.* (2020) 'Burden of Chronic Kidney Disease by KDIGO Categories of glomerular filtration rate and albuminuria: a Systematic review,' *Advances in Therapy*, 38(1), pp. 180–200. <https://doi.org/10.1007/s12325-020-01568-8>.

- Nangaku, M. (2005) 'Chronic hypoxia and tubulointerstitial injury,' *Journal of the American Society of Nephrology*, 17(1), pp. 17–25.
<https://doi.org/10.1681/asn.2005070757>.
- Nassar, W. *et al.* (2016) 'Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases', *Biomaterials Research*, 20(1). doi:10.1186/s40824-016-0068-0.
- Nowak, N., Yamanouchi, M. and Satake, E. (2021) 'The nephroprotective properties of extracellular vesicles in experimental models of chronic kidney disease: A systematic review', *Stem Cell Reviews and Reports*, 18(3), pp. 902–932. doi:10.1007/s12015-021-10189-9.
- O'Sullivan, J. *et al.* (2019) 'Refining the mouse subtotal nephrectomy in male 129s2/Sv mice for consistent modeling of progressive kidney disease with renal inflammation and cardiac dysfunction', *Frontiers in Physiology*, 10. doi:10.3389/fphys.2019.01365.
- Pazianas, M. and Miller, P.D. (2020) 'Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management,' *Journal of Bone Metabolism*, 27(1), p. 1. <https://doi.org/10.11005/jbm.2020.27.1.1>.
- Pickett, J.R. *et al.* (2023) 'Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1–directed novel therapeutics,' *Cardiovascular Research*, 119(13), pp. 2278–2293. <https://doi.org/10.1093/cvr/cvad130>.
- Ren, J. and Dai, C. (2019) 'Pathophysiology of chronic kidney disease', *Chronic Kidney Disease*, pp. 13–32. doi:10.1007/978-981-32-9131-7_2.
- Rota, C., Morigi, M. and Imberti, B. (2019) 'Stem cell therapies in kidney diseases: Progress and challenges', *International Journal of Molecular Sciences*, 20(11), p. 2790. doi:10.3390/ijms20112790.
- Ruan, G. *et al.* (2014) 'Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice', *Journal of Immunology Research*, 2014, pp. 1–13. doi:10.1155/2014/530501.
- Sarakpi, T., Mesic, A. and Speer, T. (2023) 'Leukocyte–endothelial interaction in CKD', *Clinical Kidney Journal*, 16(11), pp. 1845–1860. doi:10.1093/ckj/sfad135.
- Schnaper, H.W. *et al.* (2010) 'A conceptual framework for the molecular pathogenesis of progressive kidney disease', *Pediatric Nephrology*, 25(11), pp. 2223–2230. doi:10.1007/s00467-010-1503-4.

- Schnaper, H.W. (2013) 'Remnant nephron physiology and the progression of chronic kidney disease,' *Pediatric Nephrology*, 29(2), pp. 193–202. <https://doi.org/10.1007/s00467-013-2494-8>.
- Schnaper, H.W. (2017) 'The tubulointerstitial pathophysiology of progressive kidney Disease,' *Advances in Chronic Kidney Disease*, 24(2), pp. 107–116. <https://doi.org/10.1053/j.ackd.2016.11.011>.
- Shi, Y. *et al.* (2022) 'Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced Nash in a mouse model', *Stem Cell Research & Therapy*, 13(1). doi:10.1186/s13287-022-03201-7.
- Short, S.A.P. *et al.* (2024) 'Endothelial dysfunction biomarkers and CKD incidence in the regards cohort', *Kidney International Reports*, 9(7), pp. 2016–2027. doi:10.1016/j.ekir.2024.04.056.
- Theofilis, P. *et al.* (2021) 'Inflammatory mechanisms contributing to endothelial dysfunction,' *Biomedicines*, 9(7), p. 781. <https://doi.org/10.3390/biomedicines9070781>.
- Videm, V. and Albrigtsen, M. (2008) 'Soluble ICAM-1 and VCAM-1 as markers of Endothelial Activation', *Scandinavian Journal of Immunology*, 67(5), pp. 523–531. doi:10.1111/j.1365-3083.2008.02029.x.
- Wang, J., Zheng, Y., Li, Y., Xiao, Y., Ren, Y., & Tian, Y. (2025). Emerging role of mesenchymal stem cell-derived exosomes in the repair of acute kidney injury. *World Journal of Stem Cells*, 17(3). <https://doi.org/10.4252/wjsc.v17.i3.103360>
- Wilson, S. *et al.* (2021) 'Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk', *The Journal of Clinical Hypertension*, 23(4), pp. 831–834. doi:10.1111/jch.14186.
- Xiang, E. *et al.* (2020) 'Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis', *Stem Cell Research & Therapy*, 11(1). doi:10.1186/s13287-020-01852-y.
- Yang, J. and He, W. (2020) *Chronic Kidney Disease Diagnosis and Treatment Vol 1*. Springer Nature Singapore Pte Ltd.
- Yu, K.Y. *et al.* (2021) 'Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis', *Lupus*, 30(7), pp. 1039–1050. doi:10.1177/09612033211004727.

- Yu, Y. *et al.* (2023) 'Human umbilical cord mesenchymal stem cell exosome-derived mir-874-3P targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage', *Cellular & Molecular Biology Letters*, 28(1). doi:10.1186/s11658-023-00425-0.
- Yang, Z. *et al.* (2025) 'Umbilical cord mesenchymal stem cell exosomal mir-143-3p delays endothelial cell senescence through targeting COX-2', *PLOS One*, 20(7). doi:10.1371/journal.pone.0327173.
- Zaki, Y.Y. *et al.* (2015) *Serum Levels of Intercellular Adhesion Molecules, Vascular Cell Adhesion Molecules, and C - reactive Protein in Chronic Renal Failure Patients Receiving Haemodialysis with Different Etiology*, *International Journal of Pharmaceutical Sciences Review and Research*.
- Zhong, K., Zhang, H., Fang, Y., Lan, Q., Zhou, Z., Zhao, Y., Qiao, Y., Li, J., & Yang, B. (2023). Acute kidney injury: microRNAs and new therapeutic opportunities for natural products. *Traditional Medicine Research*, 8(11), 61. <https://doi.org/10.53388/tmr20230616001>